Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015102 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Elisabeth Anne Adanma Obara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Faculty of Health Sciences, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Nielsine Nielsens V…. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide, Migraine Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Biotechnology Center for Cellular Communication, Lundbeck Foundation, Danish Biotechnology Center for Cellular Communication and the Lundbeck Foundation.
Abstract (Originalsprache)
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a naturally occurring neuropeptide found in both the central and peripheral nervous systems of vertebrates. Recent studies have revealed the presence of PACAP and its corresponding receptors, namely, the pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R), vasoactive intestinal peptide receptor 1 (VIPR1), and vasoactive intestinal peptide receptor 2 (VIPR2), in various structures implicated in migraine pathophysiology, including sensory trigeminal neurons. Human studies have demonstrated that when infused, PACAP can cause dilation of cranial vessels and result in delayed migraine-like attacks. In light of this, we present a novel ELISA assay that has been validated for quantifying PACAP in tissue extracts and human plasma. Using two well characterized antibodies specifically targeting PACAP, we successfully developed a sandwich ELISA assay, capable of detecting and accurately quantifying PACAP without any cross-reactivity to closely related peptides. The quantification range was between 5.2 pmol/L and 400 pmol/L. The recovery in plasma ranged from 98.2% to 100%. The increasing evidence pointing to the crucial role of PACAP in migraine pathophysiology necessitates the availability of tools capable of detecting changes in the circulatory levels of PACAP and its potential application as a reliable biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Faculty of Health Sciences, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Nielsine Nielsens Vej 4, 2400 Copenhagen, NV, Denmark.
ORCID-Profile: Jens Hannibal
Förderung
- Danish Biotechnology Center for Cellular Communication
- Lundbeck Foundation
- Danish Biotechnology Center for Cellular Communication and the Lundbeck Foundation
Zitieren
APA
Obara, E. A. A., Georg, B., & Hannibal, J. (2023). Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015102
Vancouver
Obara EAA, Georg B, Hannibal J. Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015102
BibTeX
@article{Obara2023,
author = {Obara, Elisabeth Anne Adanma and Georg, Birgitte and Hannibal, Jens},
title = {Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015102}
}
EUVIMED